Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists.
Tjernberg
P
P
Van Der Heijden
J F
JF
Eikenboom
J C J
JC
Reitsma
P H
PH
D000925:Anticoagulants / Q000494:pharmacology*; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005091:Exons; D006470:Hemorrhage / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D011110:Polymorphism, Genetic; D012306:Risk; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014841:von Willebrand Factor / Q000235:genetics*
D000925:Anticoagulants; D014841:von Willebrand Factor; D014812:Vitamin K